Segment-specific Pulse Wave Velocity and Subclinical Cardiac Overload and Damage in Older Adults: The Atherosclerosis Risk in Communities (ARIC) Study by Liu, Shuiqing
 
SEGMENT-SPECIFIC PULSE WAVE VELOCITY AND 
SUBCLINICAL CARDIAC OVERLOAD AND DAMAGE IN OLDER 






A thesis submitted to Johns Hopkins University in conformity with the requirements for 







© 2016 Shuiqing Liu 




Background: Arterial stiffness, often assessed as pulse wave velocity (PWV), 
independently predicts cardiovascular disease. However, few studies have explored the 
associations of segment-specific PWV measures with biomarkers of both cardiac 
overload (N-terminal pro-B-type natriuretic peptide, NT-proBNP) or damage (high 
sensitivity cardiac troponin T, hs-cTnT) among adults without clinical cardiovascular 
disease. 
Methods: We examined PWV for six segments (cf [carotid-femoral], hc [heart-carotid], 
hf [heart-femoral], ha [heart-ankle], ba [brachial-ankle], and fa [femoral-ankle]) and their 
associations with NT-proBNP and hs-cTnT in 2,845 Caucasian and African American 
participants of the ARIC Study aged 67-90 years and without clinical history of 
cardiovascular disease. We conducted a cross-sectional analysis of data collected in 
2011-13 using linear and logistic regression models with adjustment for demographic 
characteristics, traditional cardiovascular risk factors, and echo parameters of left 
ventricular (LV) remodeling and function. 
Results: Most PWV measures demonstrated J- or U-shaped associations with NT-
proBNP and hs-cTnT. Higher values of central PWV measures (cfPWV, hcPWV, and 
hfPWV) tended to be associated with higher levels of NT-proBNP, independently of 
demographic characteristics. The associations were attenuated after additional 
adjustment for clinical cardiovascular risk factors but remained borderline significant for 
hcPWV with NT-proBNP (but not with hs-cTnT). The other three PWV measures 
including peripheral elements (haPWV, baPWV, and faPWV) had overall less evident 
positive associations with cardiac biomarkers. faPWV, reflecting peripheral arterial 
stiffness, was inversely associated with both cardiac biomarkers. Inverse association 
that higher values of NT-proBNP in the lowest quartile than in the second quartile were 
  
 iii 
seen in six PWV measures and were most robust in PWV measures incorporating 
peripheral component. 
Conclusion: Overall, the positive associations between PWV and cardiac biomarkers 
were more evident for central stiffness measures than for peripheral measures of PWV 
and were stronger for NT-proBNP than for hs-cTnT among this population of older adults 
without prevalent cardiovascular disease. Our findings suggest the importance of central 
arterial stiffness over peripheral arterial stiffness in the development of subclinical 
cardiac overload. 
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I am interested in cardiac biomarkers and the association of arterial stiffness with 
cardiac biomarkers. It has been shown that the prevalence of arterial stiffness is high in 
older adults and arterial stiffness is involved at early stage of pathophysiological process 
to cardiac disease. Therefore, I was motivated to investigate the association of pulse 
wave velocity with cardiac overload (natriuretic peptide) and damage (cTnT). To our 
knowledge, this is the first study to comprehensively examine central and peripheral 
PWV measures with both NT-proBNP and hs-cTnT exclusively in older adults without 
prevalent cardiovascular disease. I hope our findings can contribute to future research in 
the relative field. 
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Arterial stiffness indicates increased rigidity and decreased elasticity of the 
arterial wall in response to blood pressure changes1-3 and is considered as an important 
characteristic of aging process.4 When arteries are stiff (less compliant), left ventricular 
(LV) end-systolic pressure increases and therefore the heart requires increased energy 
to ensure adequate blood output to the body.4-5 Over time, this leads to LV hypertrophy, 
concentric remodeling,6 and diastolic dysfunction.5, 7 Indeed, parameters of arterial 
stiffness (particularly carotid-femoral pulse wave velocity [cfPWV] reflecting central 
arterial stiffness) are shown to independently predict cardiovascular disease (CVD).8-11  
Indicating the involvement of arterial stiffness at early stage of pathophysiological 
process to cardiac disease, several studies have demonstrated the association between 
arterial stiffness and cardiac biomarkers including natriuretic peptides (BNP)12-17 and 
cardiac troponin T (cTnT),18-20 among those without clinical cardiac disease. However, 
only one of these studies analytically accounted for parameters of cardiac structure and 
function,15 leaving uncertainty regarding whether arterial stiffness contributes to cardiac 
overload or damage before the manifestation of LV hypertrophy or remodeling. Also, 
most of these studies focused on either natriuretic peptides12-17 or cTnT18-20 (but not 
both) and were conducted in clinical populations14-16, 19-20 (e.g., patients with 
hypertension15-16, 19 or chronic kidney disease14, 20), and included a small number of 
participants (e.g., n< 1000).13-16, 19-20 In addition, only a few prior studies have 
investigated arterial stiffness in multiple vascular beds.12, 16  
Therefore, we undertook a cross-sectional study to examine the associations of 
segment-specific PWV measures, with biomarkers of both cardiac overload (natriuretic 
peptide) and damage (cTnT) in a large sample of community-dwelling older adults in the 






  The ARIC Study is a community-based cohort study originally designed to 
investigate risk factors for subclinical and clinical cardiovascular disease. The study 
recruited 15,792 participants aged 45-64 years at the baseline examination (visit 1) 
during 1987-1989 from four U.S. communities: Forsyth County, North Carolina; Jackson, 
Mississippi; suburbs of Minneapolis, Minnesota; and Washington County, Maryland.21 
The participants were invited for three short-term reexaminations, three years apart (visit 
2 in 1990-1992, visit 3 in 1993-1995, and visit 4 in 1996-1998). Visit 5 took place from 
2011-2013. A sixth visit is ongoing.  
  There were 6,538 participants who attended the fifth ARIC examination (visit 5) 
and were seen in the clinic between June 1, 2011 and August 30, 2013. At visit 5, the 
participants were aged 66-90 years and PWV was systematically assessed for the first 
time in the study. Of these 6,538 participants, we excluded 18 non-Caucasian/non-
African American participants and 1,704 participants without any of six PWV measures. 
We also excluded 387 participants with clinical conditions questioning the validity of 
PWV measurement including BMI>40 or missing BMI (n=143), severe arrhythmias 
(n=133), self-reported aortic surgery (n=48), history of peripheral revascularization 
(n=24), aortic aneurysm (n=2), aortic stenosis and aortic regurgitation (n=34), and LV 
ejection fraction <30% (n=3). We additionally excluded 305 participants with any of 
cfPWV, hcPWV, hfPWV, or higher value of right and left of haPWV, baPWV and faPWV 
measures that were greater than 3 standard deviations from their respective means. 
Since we were interested in the association of arterial stiffness with cardiac biomarkers 
in the absence of clinical cardiovascular disease, we also excluded 611 participants with 
history of heart failure (prior hospitalization with heart failure or heart failure diagnosis 
confirmed with participants’ physicians) or coronary heart disease (CHD) (self-reported 
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history at visit 1 or incident cases during follow-up prior to visit 5). We additionally 
excluded 95 participants missing NT-proBNP or hs-cTnT and 573 participants missing 
covariates of interest, leaving 2,845 participants for our analysis.   
Pulse wave velocity 
  PWV is usually defined as the distance between two arterial sites divided by the 
time that it takes for the wave to travel that distance.22 Using an oscillometry-based 
device, VP-1000plus (Omron Healthcare, Kyoto, Japan),23-24 PWV was measured for the 
following segments: carotid-femoral (cf), heart-carotid (hc), heart-femoral (hf), heart-
ankle (ha), brachial-ankle (ba), and femoral-ankle (fa). The measurement was repeated 
after 2-5 minutes and the mean PWV was recorded for each segment. Previous study 
stated acceptable repeatability for all PWV measures used in this study.25 For haPWV, 
baPWV, and faPWV, we used the higher value of left and right PWV in our primary 
analyses. Given the measured segments, cfPWV, hfPWV, and hcPWV are considered to 
reflect central arterial stiffness, haPWV and baPWV reflect both central and peripheral 
arterial stiffness, and faPWV reflects peripheral arterial stiffness.25-26 
Cardiac biomarkers 
  NT-proBNP, a biomarker of cardiac overload,27 and high-sensitivity cTnT (hs-
cTnT), a biomarker of subclinical cardiac damage,28 were measured at visit 5 on the 
Roche Elecsys 2010 Analyzer (Roche Diagnostics, Indianapolis, IN 46250) using 
immunoassay method with sandwich principle.23 The total duration of assay was 18 
minutes. 
Covariates of interest 
  All variables were collected at visit 5 except education level (high school or lower 
vs. college or above), which was recorded at visit 1. Age, gender, race, smoking status 
(current vs. former/never) and alcohol consumption (current vs. former/never) were self-
reported. Body mass index was calculated by dividing weight (kg) by the square of 
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height (m). Total cholesterol was determined via an enzymatic determination method.29 
After a 5-minute rest, sitting blood pressure was measured three times using OMRON 
machine in the right arm (unless specific conditions prohibited using right arm), and the 
mean of the last two measurements was recorded. Hypertension was defined as systolic 
blood pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg, or using medication for 
high blood pressure. Information on physical activity during leisure time was assessed 
as a composite score of frequency of TV viewing (“never” as score 5 and “very often” as 
1), walking (“never” as score 1 and “very often” as 5), and bicycling (“never” as score 1 
and “very often” as 5). Medication use in the past 4 weeks was based on 2004 med code 
including self-report or medication data files. Diabetes was defined as hemoglobin A1C 
≥6.5%, fasting glucose ≥126 mg/dL, or using diabetic medication or self-report 
diagnosis of diabetes. Reduced kidney function was defined as creatinine-based 
estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2,30 and urine 
albumin/creatinine ratio (ACR) ≥30 mg/g was considered as kidney damage.31 LV 
hypertrophy was defined as LV mass index (LVMI) >115 g/m2 for male and >95 g/m2 for 
female.32 Concentric remodeling was determined by relative wall thickness >0.42.32 
Diastolic dysfunction was measured as left atrial volume index (LAVI) ≥34 ml/m2.33 
These three cardiac measures were based on echocardiogram during visit 5. 
Statistical Analysis  
  Participants’ median (interquartile interval) of NT-proBNP and hs-cTnT were 
calculated, respectively. Baseline characteristics of participants were compared across 
quartiles of each PWV measure, with a particularly focus on cfPWV since cfPWV has 
been regarded as a representative measure of arterial stiffness;25, 34 differences were 
evaluated using ANOVA for continuous variables and the Pearson chi-squared test for 
categorical factors. Then, to evaluate the general pattern of the association of each PWV 
measure with NT-proBNP and hs-cTnT, we graphically displayed the mean levels of 
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each log-transformed cardiac biomarker adjusted to study averages of demographic 
variables (i.e., age, gender, race, education, and study center) using linear regression 
models. To allow for potential changes in slope, each PWV measure was modeled with 
linear spline terms with knots at the quartiles.  
  Since we observed non-linear relationships (often J- or U-shaped) in several 
combinations of PWV measures and cardiac biomarkers, subsequently every PWV 
measure was modeled with its quartiles to compare the strength of association across 
six PWV measures, with the second quartile as the reference. To assess the impact of 
potential confounders, we adjusted for three sets of covariates. Model 1 was adjusted for 
age, gender, race, education, and study center. Model 2 included all variables in Model 1 
plus body mass index, systolic blood pressure, hypertension medication use, smoking 
status, alcohol consumption, physical activity, diabetes, total cholesterol, reduced kidney 
function, and kidney damage. Model 3 adjusted for all variables in Model 2 plus echo 
parameters of LV remodeling and function (LV hypertrophy, concentric remodeling, and 
diastolic dysfunction). We conducted analyses with NT-proBNP and hs-cTnT modeled 
as continuous independent variables with log-transformation (linear regression) and 
binary variables based on clinical cutpoints for elevations in each measure (i.e., NT-
proBNP ≥300 vs <300 pg/ml 35-36 or hs-cTnT ≥14 vs <14 ng/L37-39) (logistic regression). 
All statistical analyses were performed using Stata version 13. P-values <0.05 were 









Among 2,845 participants, the mean age was 75.0 (SD 4.9) years, 62.3% 
(n=1,772) were female, and 23.2% (n=661) were African American. The median 
(interquartile interval) of NT-proBNP and hs-cTnT were 106.1 (57.6-200.9) pg/mL and 
10.0 (7.0-14.0) ng/L, respectively. Baseline characteristics of our study population were 
summarized across the quartiles of cfPWV in Table 1. Compared to the participants in 
the lowest quartile (cfPWV ≤950.5 cm/s), those with higher cfPWV were more likely to 
be older, African American, and less educated and to have comorbidities such as 
hypertension, diabetes, reduced kidney function, and kidney damage. The prevalence of 
left ventricular hypertrophy and concentric remodeling were more common at higher 
values of cfPWV. Participants with higher values of other five PWV measures tended to 
be older and had higher systolic blood pressure compared to their counterparts with 
lower values but showed varying patterns for other factors (Supplementary Table 1-5). 
Specifically, the prevalence of diabetes, reduced kidney function, and kidney damage 
were positively correlated with hcPWV and hfPWV, but this pattern for haPWV and 
baPWV was evident only for the presence of kidney damage. In contrast, the prevalence 
of diabetes and reduced kidney function were inversely with faPWV (the prevalence of 
kidney damage was similar across the quartiles of faPWV). The prevalence of left 
ventricular hypertrophy and diastolic dysfunction were also inversely correlated with 
faPWV, whereas at least one of three cardiac echo parameters showed positive 
associations with the other four PWV measures. 
Correlation coefficients of six PWV measures are summarized in Supplementary 
Table 6. The highest correlation was seen between two measures reflecting central 
stiffness, cfPWV and hfPWV (correlation coefficient of 0.853). Overall, hcPWV showed 
weak to modest correlations with all other five PWV measures, with the highest 
correlation of 0.427 with hfPWV. The three PWV measures that reflect peripheral 
  
 7 
stiffness had moderate to strong correlations with each other (correlation coefficients 
ranging from 0.526 to 0.763). Of those peripheral measures, haPWV showed the 
strongest correlation with central measures, followed by baPWV. There was very weak 
correlation between faPWV and any of three central stiffness measures.    
Figure 1 shows mean values of NT-proBNP and hs-cTnT according to six site-
specific PWV measures after adjusting to average values of each demographic variable. 
For NT-proBNP, J- or U-shaped associations were observed for all the PWV measures 
except baPWV and faPWV, which overall demonstrated inverse associations. The slope 
for the association with NT-proBNP was steepest for hfPWV followed by cfPWV, hcPWV, 
and haPWV. The patterns in unadjusted models were generally consistent with that in 
the demographically adjusted models, although baPWV tended to show a U-shaped 
association in unadjusted model (Supplementary Figure 2). When we analyzed hs-cTnT, 
the associations were generally flatter (shallower slope) for every PWV compared to that 
for NT-proBNP.  
Given the non-linear associations observed in Figure 1 (particularly for NT-
proBNP), we subsequently modeled quartiles of each PWV measure with their second 
quartile as the reference and log-transformed NT-proBNP and hs-cTnT as continuous 
independent variables (Tables 2 and 3). When we adjusted for demographic variables 
(Model 1), the highest quartile (Q4) of PWV measures reflecting central arterial stiffness 
(cf, hc, and hf) as well as haPWV were significantly positively associated with higher 
values of NT-proBNP (Table 2). The third quartile (Q3) was significantly different only for 
hfPWV. Once we further adjusted for cardiovascular risk factors (Model 2 in Table 2), 
only the association for hcPWV remained borderline significant (p=0.094). However, this 
association was no longer borderline significant after additionally accounting for cardiac 
echo parameters (Model 3 in Table 2). faPWV, a measure of peripheral arterial stiffness, 
showed an inverse association with NT-proBNP. Significantly higher values of NT-
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proBNP in the lowest quartile were seen not only in faPWV but also in haPWV and 
baPWV, two measures reflecting both central and peripheral arterial stiffness, as well as 
cfPWV (in Model 2) and hfPWV (in all Models).  
Overall the associations of six PWV measures with hs-cTnT (Table 3) were less 
evident than those for NT-proBNP (Table 2). Specifically, the associations of the highest 
quartile (Q4) of cfPWV and hfPWV with higher levels of hs-cTnT were borderline 
significant (p value = 0.088 for cfPWV and p value =0.073 for hfPWV) in Model 1. 
Significantly higher value of hs-cTnT in the third quartile (Q3) but not in the highest 
quartile (Q4) was observed for baPWV in Model 1 and Model 3. faPWV was inversely 
correlated with hs-cTnT, with a significantly higher average value in the lowest quartile, 
in Model 1.  
In analyses with NT-proBNP and hs-cTnT modeled as binary outcomes (NT-
proBNP ≥300pg/ml (N=375) or hs-cTnT ≥14ng/L (N=768) (Tables 4 and 5), associations 
were less evident than in the continuous analyses (Tables 2 and 3). Nonetheless, the 
general patterns were similar, with positive associations between greater central 
stiffness measures and NT-proBNP (particularly hcPWV in Model 1) (Table 4). We also 
observed significantly higher odds of NT-proBNP elevation in the lowest vs. second 
quartile for some PWV measures, and more evident associations for NT-proBNP than 










Among community-dwelling older adults without prevalent cardiovascular disease 
(heart failure or CHD), higher values of central PWV measures (cfPWV, hcPWV, and 
hfPWV) were associated with higher levels of NT-proBNP, independently of 
demographic characteristics. Although the associations were considerably attenuated 
after adjustment for traditional cardiovascular risk factors, the associations of hcPWV 
with higher levels of NT-proBNP (but not for hs-cTnT) remained borderline significant 
(but not after additionally accounting for LV remodeling). The positive associations of the 
other three PWV measures, including those that specifically reflect peripheral arterial 
stiffness (haPWV, baPWV, and faPWV), with cardiac biomarkers were overall less 
evident. FaPWV, which exclusively reflects peripheral stiffness, was overall inversely 
associated with both cardiac biomarkers. Of interest, higher values of NT-proBNP in the 
lowest quartile than in the second quartile were seen with most PWV measures, but this 
pattern was most consistent in PWV measures that incorporate a peripheral component. 
To our knowledge, this is the first study to comprehensively examine central and 
peripheral PWV measures with both NT-proBNP and hs-cTnT exclusively in older adults 
without prevalent cardiovascular disease. Our main findings for the positive association 
between measures of central arterial stiffness and cardiac biomarkers are fundamentally 
consistent with previous studies.14-18, 20 However, the associations in our study were 
overall weaker (i.e., borderline significant association seen only for hcPWV with NT-
proBNP after adjusting for potential confounders) than some of the previous studies.12, 16-
18 PWV measurement issues are often important to consider when associations are 
weaker than expected. However it seems unlikely that it would be the case in the ARIC 
Study, since PWV was measured by trained and certified technicians using state-of-the 
art machines, with acceptable repeatability.25 Our unique study population, exclusively 
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older Caucasian and African American (mean age of 75.0 years and age range 67-90 
years), may play some role behind the weaker association. For example, arterial 
stiffness is very common at older ages, and thus, the variation of PWV measures may 
be reduced in older adults, potentially attenuating observed associations with risk factors 
in this specific population. Confirmatory investigations specifically in older adults are 
warranted, especially since a recent Chinese study with ~1,500 individuals reported 
opposite patterns: stronger associations of cfPWV with hs-cTnT levels in older adults 
(≥60 years) than in younger individuals (<60 years) with ours.18   
We found the overall associations between central PWV measures (cfPWV, 
hcPWV, and hfPWV) with both NT-proBNP were more evident than that of PWV 
measures including peripheral element (haPWV, baPWV, and faPWV). This result was 
consistent with three previous studies12, 16, 18 that investigated the association of both 
central and peripheral PWV measures with NT-proBNP or hs-cTnT. This observation 
may highlight the pathophysiological importance of central arterial stiffness over 
peripheral arterial stiffness. This finding is intuitive since central arteries are anatomically 
closest to the heart and their elasticity is key for effective cardiac function, i.e., 
ventricular-vascular coupling.40 Thus, their abnormal changes may impact the heart 
more than that of more distal arteries such as the femoral and popliteal.41-42  
The inverse associations we found between faPWV, the measure purely 
reflecting peripheral stiffness, with both cardiac biomarkers are consistent with previous 
studies. Although to our knowledge, our study is the first to show an inverse relationship 
for faPWV, two studies similarly reported such an inverse association for carotid-radial 
PWV (another measure of peripheral stiffness) among adults without cardiovascular 
disease.12, 16 The pathophysiological meaning of this inverse correlation is not clear, but 
this finding may be related to the fact that the PWV value of the lower-limb arteries might 
be lower when significant stenosis exists in the leg arteries.43 More specifically, some of 
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those in the lowest category of PWV may have peripheral artery disease, a condition 
prevalent in older adults44 and known to be associated with high risk of heart failure.45-46  
The associations with PWV measures were more evident for NT-proBNP than for 
hs-cTnT in our study. This observation is largely consistent with the only previous study 
simultaneously assessing both NT-proBNP and hs-cTnT for their associations with 
arterial stiffness.47 This result is consistent with the concept of ventricular-vascular 
coupling as a key element behind the development of heart failure, as NT-proBNP is 
known to reflect volume overload and ventricular wall tension.48 On the other hand, the 
actual mechanisms leading to the release of hs-cTnT to systemic circulation in persons 
without acute coronary syndrome are not well understood. Although future studies are 
needed for confirmation, our study suggests that neither of central nor peripheral arterial 
stiffness may play a pivotal role in the subclinical elevation of hs-cTnT, at least in older 
adults.  
We found higher values of NT-proBNP in the lowest quartile compared to the 
second quartile for most central and peripheral PWV measures tested, resulting in 
overall J- or U-shaped associations between PWV and NT-proBNP. We did not find 
previous studies reporting a similar pattern for central PWV measures with NT-proBNP 
and the actual reasons of such an association are unclear. Nonetheless, there are a few 
plausible mechanisms. Such a J-shaped association between clinical characteristics and 
cardiovascular risk has been shown for various factors, like blood pressure,49 glucose,50 
and adiposity.51 Thus, there may be a group of individuals in the lowest quartile of PWV 
measures with latent high risk of cardiac conditions. Another possibility may be related to 
beneficial effects of natriuretic peptides, e.g., vasodilation and glucose utilization. So, it 
may be possible that in some individuals relatively high biological levels of natriuretic 
peptides lead to better artery function such as lower PWV values. Unfortunately, given 
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the cross-sectional design of the present study, we cannot elucidate the temporality of 
PWV and cardiac biomarkers. 
Our findings may have several clinical and research implications. Although many 
parameters reflecting arterial stiffness have been proposed and are under 
investigation,22 our results suggest the importance of focusing on those reflecting central 
arterial stiffness. Among parameters of central arterial stiffness, cfPWV has been 
considered as a gold standard.52 However, our results of similar or sometimes stronger 
relationships of hcPWV and hfPWV over cfPWV suggest the potential usefulness of 
those alternative central measures for assessing cardiac health. Of note, hfPWV does 
not require carotid probe, which can sometimes be cumbersome to technicians and the 
subject, and thus may have technical advantage over cfPWV or hcPWV in some settings. 
In addition to the inherent limitations of the cross-sectional design, there are a 
few other limitations of our study that should be considered in the interpretation of these 
data. As with any observational study, we cannot rule out the possibility of residual 
confounding. Also, generalization of our findings to younger population or ethnic groups 
other than Caucasian or African American may be problematic. 
In conclusion, among older adults with high PWV values and without prevalent 
cardiovascular disease, central PWV measures (i.e., cfPWV, hcPWV and hfPWV) were 
associated with higher levels of NT-proBNP but not strongly associated with hs-cTnT. 
On the other hand, faPWV, which exclusively reflects peripheral arterial stiffness, was 
inversely associated with both cardiac biomarkers. Our study supports the 
pathophysiological importance of central arterial stiffness over peripheral arterial 
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Main Tables and Figures 
Table 1. Demographic and clinical characteristics of study participants overall and according to cfPWV quartile categories, 
















   Age (years) 75.0 ± 4.9 73.4 ± 4.4 74.2 ± 4.6 75.5 ± 5.0 76.8 ± 5.1 <0.001 * 
   Females, n (%) 1772 (62.3) 464 (64.8) 444 (62.8) 434 (61.0) 430 (60.5) 0.324 
   African American, n (%) 661 (23.2) 139 (19.4) 140 (19.8) 161 (22.6) 221 (31.1) <0.001 * 
   High school or lower education, n (%)  1524 (53.6) 335 (46.8) 370 (52.3) 388 (54.6) 431 (60.6) <0.001 * 
   Study center      <0.001 * 
       Forsyth County, North Carolina 590 (20.7) 168 (23.5) 147 (20.8) 136 (19.1) 139 (19.6) 
       Jackson, Mississippi 617 (21.7) 129 (18.0) 124 (17.5) 155 (21.8) 209 (29.4) 
       Suburban Minneapolis, Minnesota 862 (27.3) 223 (31.2) 251 (35.5) 210 (29.5) 178 (25.0) 
       Washington County, Maryland 776 (27.0) 196 (27.4) 185 (26.2) 210 (29.5) 185 (26.0) 
   Body Mass Index (kg/m2) 28.0 ± 4.5 28.0 ± 4.3 28.4 ± 4.6 27.9 ± 4.4 27.6 ± 4.5 0.020 * 
   Systolic blood pressure (mmHg) 130.4 ± 17.0 122.7 ± 15.2 128.4 ± 15.1 132.7 ± 16.2 137.8 ± 17.7 <0.001 * 
   Diastolic blood pressure (mmHg) 66.7 ± 9.9 64.8 ± 9.5 66.9 ± 9.7 67.3 ± 10.1 67.6 ± 10.2 <0.001 * 
   Antihypertensive medication, n (%)  1969 (69.2) 430 (60.1) 484 (68.5) 513 (72.2) 542 (76.2) <0.001 * 
   Diabetes, n (%) 956 (33.6) 178 (24.9) 227 (32.1) 242 (34.0) 309 (43.5) <0.001 * 
   Current smoker, n (%) 153 (5.4) 46 (6.4) 35 (5.0) 41 (5.8) 31 (4.4) 0.327 
   Current drinker, n (%) 1432 (50.3) 398 (55.6) 385 (54.5) 361 (50.8) 288 (40.5) <0.001 * 
   Physical activity score 2.3 ± 0.6 2.3 ± 0.6 2.4 ± 0.6 2.3 ± 0.6 2.2 ± 0.6 <0.001 * 
   Total cholesterol (mmol/L) 4.8 ± 1.1 4.9 ± 1.0 4.9 ± 1.0 4.9 ± 1.1 4.8 ± 1.1 0.124 
   Reduced kidney function, n (%) 686 (24.1) 147 (20.5) 164 (23.2) 163 (22.9) 212 (29.8) <0.001 * 
   Kidney damage, n (%) 425 (14.9) 67 (9.4) 77 (10.9) 126 (17.7) 155 (21.8) <0.001 * 
   Left ventricular hypertrophy, n (%) 234 (8.2) 53 (7.4) 51 (7.2) 52 (7.3) 78 (11.0) 0.024* 
   Concentric remodeling, n (%) 1274 (44.8) 277 (38.7) 319 (45.1) 312 (43.9) 366 (51.5) <0.001 * 
   Diastolic dysfunction, n (%) 288 (10.1) 78 (10.9) 65 (9.2) 74 (10.4) 71 (10.0) 0.749 
Values are expressed as mean ± SD/median (IQR) for continuous variables, n (%) for categorical variables. * P <0.05 (two sided) 
Abbreviations: SD, standard deviation; IQR, interquartile range; cfPWV, carotid-femoral pulse wave velocity. 
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Table 2. Adjusted associations of measures of regional pulse wave velocity (in quartiles) with log NT-proBNP  
 Regional 
PWV 
PWV quartile categories d 
Q1 Q2 Q3 Q4 
𝛽𝛽e(95%CI) Ref 𝛽𝛽(95%CI) 𝛽𝛽(95%CI) 
Model 1 a cfPWV 0.074 (-0.018, 0.165) 0 -0.008 (-0.099, 0.084)  0.131 (0.037, 0.225) * 
 hcPWV 0.039 (-0.053, 0.131) 0 0.053 (-0.039, 0.144)  0.129 (0.036, 0.222) * 
 hfPWV  0.151 (0.060, 0.243) * 0  0.106 (0.014, 0.197) *  0.209 (0.115, 0.303) * 
 haPWV  0.104 (0.013, 0.196) * 0 0.031 (-0.061, 0.123)  0.098 (0.005, 0.191) * 
 baPWV 0.088 (-0.004, 0.179) 0 -0.003 (-0.094, 0.089) 0.044 (-0.050, 0.137) 
 faPWV 0.079 (-0.012, 0.171) 0 0.008 (-0.084, 0.099) -0.086 (-0.178, 0.006) 
Model 2 b cfPWV  0.110 (0.021, 0.199) * 0 -0.060 (-0.148, 0.029) 0.009 (-0.083, 0.102) 
 hcPWV 0.050 (-0.039, 0.138) 0 0.020 (-0.069, 0.109) 0.077 (-0.013, 0.167) 
 hfPWV  0.199 (0.111, 0.288) * 0 0.054 (-0.034, 0.143) 0.065 (-0.029, 0.158) 
 haPWV  0.150 (0.062, 0.239) * 0 -0.035 (-0.124, 0.053) -0.053 (-0.146, 0.040) 
 baPWV  0.139 (0.050, 0.228) * 0 -0.064 (-0.152, 0.024) -0.092 (-0.184, 0.001) 
 faPWV  0.115 (0.026, 0.203) * 0 -0.021 (-0.108, 0.067)    -0.138 (-0.228, -0.049) * 
Model 3 c cfPWV 0.078 (-0.008, 0.164) 0 -0.057 (-0.143, 0.029) 0.024 (-0.066, 0.113) 
 hcPWV 0.033 (-0.052, 0.119) 0 0.016 (-0.070, 0.101) 0.061 (-0.026, 0.148) 
 hfPWV  0.158 (0.072, 0.244) * 0 0.037 (-0.049, 0.123) 0.075 (-0.016, 0.166) 
 haPWV  0.121 (0.036, 0.207) * 0 -0.019 (-0.105, 0.066) -0.032 (-0.122, 0.058) 
 baPWV  0.105 (0.018, 0.191) * 0 -0.056 (-0.142, 0.029) -0.063 (-0.152, 0.027) 
 faPWV  0.089 (0.003, 0.175) * 0 -0.001 (-0.086, 0.084)    -0.107 (-0.194, -0.021) * 
Abbreviations: PWV, pulse wave velocity; cfPWV, carotid-femoral PWV; hcPWV, heart-carotid PWV; hfPWV, heart-femoral PWV; haPWV, heart-
ankle PWV; baPWV, brachial-ankle PWV; faPWV, femoral-ankle PWV; NT-pro BNP, N-terminal pro-B-type natriuretic peptide. 
a. Model 1: Adjusted for demographic variables (age, race, gender, education level and center). 
b. Model 2: Adjusted for covariates in Model 1 + other traditional cardiovascular risk factors (body mass index, systolic blood pressure, smoking 
status, alcohol habit, physical activity, diabetes, hypertensive medication, total cholesterol, kidney function, and kidney damage). 
c. Model 3: Adjusted for covariates in Model 2 + cardiac echo parameters of left ventricular remodeling and function (left ventricular hypertrophy, 
concentric remodeling and diastolic dysfunction). 
d. Quartiles for PWV measures:  
    cfPWV: Q1, ≤950.5 (n=716); Q2, 950.5-≤1122 (n=707); Q3, 1122-≤1320.5 (n=711); Q4, >1320.5 (n=711) 
    hcPWV: Q1, ≤904  (n=712); Q2, 904-≤1059.5  (n=712); Q3, 1059.5-≤1274.5  (n=710); Q4, >1274.5  (n=711) 
    hfPWV: Q1, ≤996 (n=712); Q2, 996-≤1132.5 (n=711); Q3, 1132.5-≤1282.5 (n=711); Q4, >1282.5 (n=711) 
    haPWV: Q1, ≤1021 (n=712); Q2, 1021-≤1113 (n=713); Q3, 1113-≤1208.5  (n=709); Q4, >1208.5  (n=711) 
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    baPWV: Q1, ≤1538 (n=712); Q2, 1538-≤1728 (n=711); Q3, 1728-≤1948 (n=713); Q4, >1948 (n=709) 
    faPWV: Q1, ≤999 (n=713); Q2, 999-≤1108  (n=711); Q3, 1108-≤1224  (n=713); Q4, >1224  (n=708) 
e. Linear regression coefficient indicates the difference in log NT-proBNP between each PWV quartile category and the reference category (Q2). 










Table 3. Adjusted associations of measures of regional pulse wave velocity (in quartiles) with log hs-cTnT  
 Regional 
PWV 
PWV quartile categories d 
Q1 Q2 Q3 Q4 
𝛽𝛽e(95%CI) Ref 𝛽𝛽(95%CI) 𝛽𝛽(95%CI) 
Model 1 a cfPWV -0.009 (-0.064, 0.047) 0 0.032 (-0.024, 0.087) 0.050 (-0.007, 0.106) 
 hcPWV -0.011 (-0.067, 0.044) 0 0.018 (-0.038, 0.074) -0.002 (-0.058, 0.054) 
 hfPWV -0.005 (-0.061, 0.051) 0 0.008 (-0.048, 0.064) 0.052 (-0.005, 0.110) 
 haPWV 0.041 (-0.014, 0.097) 0 0.014 (-0.042, 0.070) -0.002 (-0.059, 0.054) 
 baPWV 0.032 (-0.023, 0.088) 0  0.058 (0.003, 0.114) *   0.0001 (-0.056, 0.057) 
 faPWV  0.062 (0.007, 0.118) * 0 -0.011 (-0.066, 0.045) -0.039 (-0.095, 0.017) 
Model 2 b cfPWV 0.014 (-0.040, 0.068) 0 0.025 (-0.029, 0.079) 0.013 (-0.043, 0.069) 
 hcPWV -0.005 (-0.058, 0.049) 0 0.009 (-0.044, 0.063) -0.016 (-0.070, 0.038) 
 hfPWV 0.014 (-0.040, 0.067) 0 0.002 (-0.052, 0.056) 0.021 (-0.036, 0.077) 
 haPWV 0.038 (-0.016, 0.091) 0   0.0001 (-0.053, 0.054) -0.026 (-0.082, 0.030) 
 baPWV 0.038 (-0.016, 0.092) 0 0.050 (-0.003, 0.104) -0.010 (-0.066, 0.046) 
 faPWV 0.049 (-0.005, 0.102) 0 -0.007 (-0.061, 0.046) -0.021 (-0.075, 0.033) 
Model 3 c cfPWV 0.007 (-0.047, 0.060) 0 0.028 (-0.025, 0.082) 0.015 (-0.040, 0.071) 
 hcPWV -0.010 (-0.063, 0.043) 0 0.006 (-0.047, 0.059) -0.019 (-0.073, 0.035) 
 hfPWV 0.004 (-0.050, 0.057) 0 -0.003 (-0.056, 0.050) 0.023 (-0.033, 0.079) 
 haPWV 0.028 (-0.025, 0.081) 0 0.004 (-0.050, 0.057) -0.022 (-0.078, 0.034) 
 baPWV 0.028 (-0.025, 0.081) 0   0.053 (0.0001, 0.106) * -0.003 (-0.058, 0.053) 
 faPWV 0.038 (-0.016, 0.091) 0 -0.004 (-0.057, 0.049) -0.015 (-0.069, 0.038) 
Abbreviations: PWV, pulse wave velocity; cfPWV, carotid-femoral PWV; hcPWV, heart-carotid PWV; hfPWV, heart-femoral PWV; haPWV, heart-
ankle PWV; baPWV, brachial-ankle PWV; faPWV, femoral-ankle PWV; hs-cTnT, high-sensitivity troponin T. 
a. Model 1: Adjusted for demographic variables (age, race, gender, education level and center). 
b. Model 2: Adjusted for covariates in Model 1 + other traditional cardiovascular risk factors (body mass index, systolic blood pressure, smoking 
status, alcohol habit, physical activity, diabetes, hypertensive medication, total cholesterol, kidney function, and kidney damage). 
c. Model 3: Adjusted for covariates in Model 2 + cardiac echo parameters of left ventricular remodeling and function (left ventricular hypertrophy, 
concentric remodeling and diastolic dysfunction). 
d. Quartiles for PWV measures:  
    cfPWV: Q1, ≤950.5 (n=716); Q2, 950.5-≤1122 (n=707); Q3, 1122-≤1320.5 (n=711); Q4, >1320.5 (n=711) 
    hcPWV: Q1, ≤904  (n=712); Q2, 904-≤1059.5  (n=712); Q3, 1059.5-≤1274.5  (n=710); Q4, >1274.5  (n=711) 
    hfPWV: Q1, ≤996 (n=712); Q2, 996-≤1132.5 (n=711); Q3, 1132.5-≤1282.5 (n=711); Q4, >1282.5 (n=711) 
    haPWV: Q1, ≤1021 (n=712); Q2, 1021-≤1113 (n=713); Q3, 1113-≤1208.5  (n=709); Q4, >1208.5  (n=711) 
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    baPWV: Q1, ≤1538 (n=712); Q2, 1538-≤1728 (n=711); Q3, 1728-≤1948 (n=713); Q4, >1948 (n=709) 
    faPWV: Q1, ≤999 (n=713); Q2, 999-≤1108  (n=711); Q3, 1108-≤1224  (n=713); Q4, >1224  (n=708) 
e. Linear regression coefficient: It indicates the difference in log hs-cTnT between each PWV quartile category and the reference category (Q2). 










Table 4. Adjusted odds ratios (95% confidence intervals) of elevated NT-proBNP (≥300pg/ml) according to measures of 
regional pulse wave velocity (in quartiles) 
 Regional 
PWV 
PWV quartile categories d 
Q1 Q2 Q3 Q4 
ORe (95%CI) Ref OR (95%CI) OR (95%CI) 
Model 1 a cfPWV 1.185 (0.849, 1.654) 1 0.962 (0.690, 1.342) 1.344 (0.977, 1.848) 
 hcPWV   1.614 (1.166, 2.236) * 1 1.251 (0.892, 1.754)   1.472 (1.053, 2.059) * 
 hfPWV 1.153 (0.829, 1.604) 1 1.008 (0.725, 1.402) 1.327 (0.962, 1.831) 
 haPWV 1.380 (0.995, 1.913) 1 1.024 (0.732, 1.434) 1.308 (0.948, 1.806) 
 baPWV 1.322 (0.949, 1.841) 1 1.022 (0.734, 1.423) 1.180 (0.857, 1.626) 
 faPWV 1.174 (0.855, 1.613) 1 1.083 (0.788, 1.488) 0.853 (0.853, 1.184) 
Model 2 b cfPWV 1.322 (0.934, 1.871) 1 0.858 (0.607, 1.211) 1.029 (0.734, 1.441) 
 hcPWV   1.700 (1.216, 2.377) * 1 1.155 (0.814, 1.638) 1.302 (0.919, 1.845) 
 hfPWV 1.298 (0.920, 1.830) 1 0.901 (0.640, 1.267) 0.949 (0.673, 1.339) 
 haPWV   1.546 (1.098, 2.178) * 1 0.895 (0.632, 1.268) 0.964 (0.682, 1.362) 
 baPWV   1.486 (1.050, 2.102) * 1 0.907 (0.644, 1.279) 0.899 (0.637, 1.267) 
 faPWV 1.260 (0.902, 1.759) 1 1.046 (0.753, 1.454) 0.785 (0.557, 1.107) 
Model 3 c cfPWV 1.256 (0.876, 1.800) 1 0.890 (0.624, 1.270) 1.095 (0.773, 1.550) 
 hcPWV   1.643 (1.164, 2.319) * 1 1.126 (0.785, 1.615) 1.255 (0.876, 1.796) 
 hfPWV 1.180 (0.828, 1.681) 1 0.845 (0.594, 1.202) 0.984 (0.691, 1.401) 
 haPWV 1.425 (0.999, 2.031) 1 0.933 (0.653, 1.333) 1.012 (0.710, 1.444) 
 baPWV 1.357 (0.948, 1.943) 1 0.932 (0.655, 1.326) 0.983 (0.689, 1.401) 
 faPWV 1.143 (0.808, 1.616) 1 1.116 (0.796, 1.565) 0.830 (0.584, 1.181) 
Abbreviations: PWV, pulse wave velocity; cfPWV, carotid-femoral PWV; hcPWV, heart-carotid PWV; hfPWV, heart-femoral PWV; haPWV, heart-
ankle PWV; baPWV, brachial-ankle PWV; faPWV, femoral-ankle PWV; NT-pro BNP, N-terminal pro-B-type natriuretic peptide. 
a. Model 1: Adjusted for demographic variables (age, race, gender, education level and center). 
b. Model 2: Adjusted for covariates in Model 1 + other traditional cardiovascular risk factors (body mass index, systolic blood pressure, smoking 
status, alcohol habit, physical activity, diabetes, hypertensive medication, total cholesterol, kidney function, and kidney damage). 
c. Model 3: Adjusted for covariates in Model 2 + cardiac echo parameters of left ventricular remodeling and function (left ventricular hypertrophy, 
concentric remodeling and diastolic dysfunction). 
d. Quartiles for PWV measures:  
    cfPWV: Q1, ≤950.5 (n=716); Q2, 950.5-≤1122 (n=707); Q3, 1122-≤1320.5 (n=711); Q4, >1320.5 (n=711) 
    hcPWV: Q1, ≤904  (n=712); Q2, 904-≤1059.5  (n=712); Q3, 1059.5-≤1274.5  (n=710); Q4, >1274.5  (n=711) 
    hfPWV: Q1, ≤996 (n=712); Q2, 996-≤1132.5 (n=711); Q3, 1132.5-≤1282.5 (n=711); Q4, >1282.5 (n=711) 
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    haPWV: Q1, ≤1021 (n=712); Q2, 1021-≤1113 (n=713); Q3, 1113-≤1208.5  (n=709); Q4, >1208.5  (n=711) 
    baPWV: Q1, ≤1538 (n=712); Q2, 1538-≤1728 (n=711); Q3, 1728-≤1948 (n=713); Q4, >1948 (n=709) 
    faPWV: Q1, ≤999 (n=713); Q2, 999-≤1108  (n=711); Q3, 1108-≤1224  (n=713); Q4, >1224  (n=708) 
e. Odds ratio in logistic regression: It indicates the ratio of odds for elevated NT-proBNP level between each PWV quartile category and the 







Table 5. Adjusted odds ratios (95% confidence intervals) of elevated hs-cTnT (≥14 ng/L) according to measures of 
regional pulse wave (in quartiles) 
 Regional 
PWV 
PWV quartile categories d 
Q1 Q2 Q3 Q4 
ORe (95%CI) Ref OR (95%CI) OR (95%CI) 
Model 1 a cfPWV 1.043 (0.797, 1.364) 1 1.135 (0.877, 1.469)   1.307 (1.011, 1.690) * 
 hcPWV 0.947 (0.723, 1.241) 1 1.143 (0.887, 1.471) 0.989 (0.766, 1.277) 
 hfPWV 1.067 (0.815, 1.399) 1 1.053 (0.812, 1.364) 1.241 (0.961, 1.603) 
 haPWV 1.216 (0.934, 1.583) 1 1.060 (0.818, 1.374) 1.121 (0.867, 1.449) 
 baPWV 1.058 (0.814, 1.377) 1 1.094 (0.849, 1.409) 1.011 (0.781, 1.308) 
 faPWV   1.344 (1.043, 1.732) * 1 1.073 (0.829, 1.389) 0.996 (0.767, 1.294) 
Model 2 b cfPWV 1.125 (0.849, 1.491) 1 1.116 (0.853, 1.460) 1.168 (0.890, 1.532) 
 hcPWV 0.986 (0.746, 1.304) 1 1.114 (0.857, 1.447) 0.923 (0.707, 1.205) 
 hfPWV 1.130 (0.853, 1.498) 1 1.026 (0.784, 1.342) 1.089 (0.828, 1.431) 
 haPWV 1.204 (0.913, 1.587) 1 1.038 (0.794, 1.358) 1.053 (0.799, 1.388) 
 baPWV 1.063 (0.808, 1.399) 1 1.078 (0.828, 1.402) 0.972 (0.738, 1.280) 
 faPWV 1.259 (0.966, 1.642) 1 1.110 (0.850, 1.450) 1.069 (0.813, 1.405) 
Model 3 c cfPWV 1.088 (0.819, 1.446) 1 1.123 (0.857, 1.472) 1.187 (0.903, 1.561) 
 hcPWV 0.963 (0.727, 1.276) 1 1.103 (0.847, 1.437) 0.903 (0.691, 1.181) 
 hfPWV 1.077 (0.811, 1.431) 1 1.001 (0.763, 1.312) 1.096 (0.833, 1.443) 
 haPWV 1.170 (0.885, 1.546) 1 1.059 (0.809, 1.388) 1.079 (0.817, 1.424) 
 baPWV 1.021 (0.774, 1.348) 1 1.087 (0.834, 1.417) 1.006 (0.763, 1.328) 
 faPWV 1.210 (0.926, 1.581) 1 1.124 (0.859, 1.472) 1.106 (0.839, 1.457) 
Abbreviations: PWV, pulse wave velocity; cfPWV, carotid-femoral PWV; hcPWV, heart-carotid PWV; hfPWV, heart-femoral PWV; haPWV, heart-
ankle PWV; baPWV, brachial-ankle PWV; faPWV, femoral-ankle PWV; hs-cTnT, high-sensitivity troponin T. 
a. Model 1: Adjusted for demographic variables (age, race, gender, education level and center). 
b. Model 2: Adjusted for covariates in Model 1 + other traditional cardiovascular risk factors (body mass index, systolic blood pressure, smoking 
status, alcohol habit, physical activity, diabetes, hypertensive medication, total cholesterol, kidney function, and kidney damage). 
c. Model 3: Adjusted for covariates in Model 2 + cardiac echo parameters of left ventricular remodeling and function (left ventricular hypertrophy, 
concentric remodeling and diastolic dysfunction). 
d. Quartiles for PWV measures:  
    cfPWV: Q1, ≤950.5 (n=716); Q2, 950.5-≤1122 (n=707); Q3, 1122-≤1320.5 (n=711); Q4, >1320.5 (n=711) 
    hcPWV: Q1, ≤904  (n=712); Q2, 904-≤1059.5  (n=712); Q3, 1059.5-≤1274.5  (n=710); Q4, >1274.5  (n=711) 
    hfPWV: Q1, ≤996 (n=712); Q2, 996-≤1132.5 (n=711); Q3, 1132.5-≤1282.5 (n=711); Q4, >1282.5 (n=711) 
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    haPWV: Q1, ≤1021 (n=712); Q2, 1021-≤1113 (n=713); Q3, 1113-≤1208.5  (n=709); Q4, >1208.5  (n=711) 
    baPWV: Q1, ≤1538 (n=712); Q2, 1538-≤1728 (n=711); Q3, 1728-≤1948 (n=713); Q4, >1948 (n=709) 
    faPWV: Q1, ≤999 (n=713); Q2, 999-≤1108  (n=711); Q3, 1108-≤1224  (n=713); Q4, >1224  (n=708) 
e. Odds ratio in logistic regression: It indicates the ratio of odds for elevated hs-cTnT level between each PWV quartile category and the reference 




















Figure 1. Predicted log NT-proBNP and hs-cTnT with regional PWV with splines by 
quartiles adjusted for demographic characteristics (age, gender, race, education, center) 
a.    b.  
c.     d.  
e.    f.  
g.    h.  
i.     j.  
k.    l.  
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Supplement Tables and Figures  
 
Supplementary Table 1. Demographic and clinical characteristics of study participants overall and according to hcPWV 















   Age (years) 75.0 ± 4.9 74.5 ± 4.8 74.7 ± 5.1 75.2 ± 4.9 75.5 ± 4.9 <0.001 * 
   Females, n (%) 1772 (62.3) 576 (80.9) 483 (67.8) 398 (56.1) 315 (44.3) <0.001 * 
   African American, n (%) 661 (23.2) 155 (21.8) 158 (22.2) 179 (25.2) 169 (23.8) 0.398 
   High school or lower education, n (%)  1524 (53.6) 409 (57.4) 374 (52.5) 387 (54.5) 354 (49.8) 0.030 * 
   Study center      0.305 
       Forsyth County, North Carolina 590 (20.7) 136 (19.1) 170 (23.9) 149 (21.0) 135 (19.0)  
       Jackson, Mississippi 617 (21.7) 151 (21.2) 148 (20.8) 163 (23.0) 155 (21.8)  
       Suburban Minneapolis, Minnesota 862 (27.3) 227 (31.9) 217 (30.5) 197 (27.8) 221 (31.1)  
       Washington County, Maryland 776 (27.0) 198 (27.8) 177 (24.9) 201 (28.3) 200 (28.1)  
   Body Mass Index (kg/m2) 28.0 ± 4.5 27.9 ± 4.8 28.1 ± 4.6 27.9 ± 4.3 27.9 ± 4.2 0.875 
   Systolic blood pressure (mmHg) 130.4 ± 17.0 128.2 ± 17.0 129.0 ± 15.8 131.8 ± 17.3 132.6 ± 17.3 <0.001 * 
   Diastolic blood pressure (mmHg) 66.7 ± 9.9 65.5 ± 9.7 66.7 ± 10.1 67.1 ± 9.6 67.4 ± 10.1 0.002 * 
   Antihypertensive medication, n (%)  1969 (69.2) 490 (68.8) 496 (69.7) 496 (69.9) 487 (68.5) 0.934 
   Diabetes, n (%) 956 (33.6) 227 (31.9) 236 (33.1) 249 (35.1) 244 (34.3) 0.602 
   Current smoker, n (%) 153 (5.4) 42 (5.9) 44 (6.2) 32 (4.5) 35 (4.9) 0.453 
   Current drinker, n (%) 1432 (50.3) 346 (48.6) 350 (49.2) 361 (50.8) 375 (52.7) 0.395 
   Physical activity score  2.3 ± 0.6 2.3 ± 0.6 2.3 ± 0.7 2.3 ± 0.7 2.3 ± 0.6 0.669 
   Total cholesterol (mmol/L) 4.8 ± 1.1 5.0 ± 1.0 4.8 ± 1.0 4.8 ± 1.1 4.7 ± 1.1 0.003 * 
   Reduced kidney function, n (%) 686 (24.1) 161 (22.6) 159 (22.3) 180 (25.4) 186 (26.2) 0.227 
   Kidney damage, n (%) 425 (14.9) 79 (11.1) 96 (13.5) 114 (16.1) 136 (19.1) <0.001 * 
   LV hypertrophy, n (%) 234 (8.2) 69 (9.7) 47 (6.6) 64 (9.0) 54 (7.6) 0.140 
   Concentric remodeling, n (%) 1274 (44.8) 319 (44.8) 324 (45.5) 331 (46.6) 300 (42.2) 0.385 
   Diastolic dysfunction, n (%) 288 (10.1) 69 (9.7) 66 (9.3) 68 (9.6) 85 (12.0) 0.312 
Values are expressed as mean ± SD/median (IQR) for continuous variables, n (%) for categorical variables. * P <0.05 (two sided) 
Abbreviations: SD, standard deviation; IQR, interquartile range; hcPWV, heart-carotid pulse wave velocity. 
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Supplementary Table 2. Demographic and clinical characteristics of study participants overall and according to hfPWV 
















   Age (years) 75.0 ± 4.9 73.4 ± 4.5 74.4 ± 4.6 75.3 ± 4.8 76.8 ± 5.2 <0.001 * 
   Females, n (%) 1772 (62.3) 505 (70.9) 473 (66.5) 426 (59.9) 368 (51.8) <0.001 * 
   African American, n (%) 661 (23.2) 132 (18.5) 135 (19.0) 164 (23.1) 230 (32.3) <0.001 * 
   High school or lower education, n (%)  1524 (53.6) 378 (53.1) 359 (50.5) 390 (54.9) 397 (55.8) 0.194 
   Study center      <0.001 * 
       Forsyth County, North Carolina 590 (20.7) 140 (19.7) 172 (24.2) 140 (19.7) 138 (19.4)  
       Jackson, Mississippi 617 (21.7) 125 (17.6) 123 (17.3) 155 (21.8) 214 (30.1)  
       Suburban Minneapolis, Minnesota 862 (27.3) 209 (29.4) 214 (30.1) 227 (31.9) 212 (29.8)  
       Washington County, Maryland 776 (27.0) 238 (33.4) 202 (28.4) 189 (26.6) 147 (20.7)  
   Body Mass Index (kg/m2) 28.0 ± 4.5 28.5 ± 4.4 28.1 ± 4.6 28.0 ± 4.5 27.2 ± 4.2 <0.001 * 
   Systolic blood pressure (mmHg) 130.4 ± 17.0 123.0 ± 15.7 127.8 ± 14.5 132.5 ± 16.2 138.2 ± 17.6 <0.001 * 
   Diastolic blood pressure (mmHg) 66.7 ± 9.9 64.6 ± 9.7 66.2 ± 9.6 67.6 ± 9.9 68.2 ± 10.1 <0.001 * 
   Antihypertensive medication, n (%)  1969 (69.2) 453 (63.6) 486 (68.4) 501 (70.5) 529 (74.4) <0.001 * 
   Diabetes, n (%) 956 (33.6) 200 (28.1) 228 (32.1) 236 (33.2) 292 (41.1) <0.001 * 
   Current smoker, n (%) 153 (5.4) 49 (6.9) 31 (4.4) 36 (5.1) 37 (5.2) 0.188 
   Current drinker, n (%) 1432 (50.3) 387 (54.4) 367 (51.6) 364 (51.2) 314 (44.2) 0.001 * 
   Physical activity score  2.3 ± 0.6 2.3 ± 0.7 2.3 ± 0.6 2.3 ± 0.7 2.2 ± 0.6 <0.001 * 
   Total cholesterol (mmol/L) 4.8 ± 1.1 4.9 ± 1.0 4.9 ± 1.0 4.8 ± 1.0 4.8 ± 1.1 0.259 
   Reduced kidney function, n (%) 686 (24.1) 143 (20.1) 163 (22.9) 169 (23.8) 211 (29.7) <0.001 * 
   Kidney damage, n (%) 425 (14.9) 65 (9.1) 83 (11.7) 112 (15.8) 165 (23.2) <0.001 * 
   LV hypertrophy, n (%) 234 (8.2) 57 (8.0) 54 (7.6) 58 (8.2) 65 (9.1) 0.749 
   Concentric remodeling, n (%) 1274 (44.8) 276 (38.8) 319 (44.9) 326 (45.9) 353 (49.6) 0.001 * 
   Diastolic dysfunction, n (%) 288 (10.1) 81 (11.4) 50 (7.0) 87 (12.2) 70 (9.8) 0.007 * 
Values are expressed as mean ± SD/median (IQR) for continuous variables, n (%) for categorical variables. * P <0.05 (two sided) 





Supplementary Table 3. Demographic and clinical characteristics of study participants overall and according to haPWV 
















   Age (years) 75.0 ± 4.9 73.7 ± 4.6 74.4 ± 4.7 75.1 ± 4.7 76.7 ± 5.2 <0.001 * 
   Females, n (%) 1772 (62.3) 493 (69.2) 470 (65.9) 423 (59.7) 386 (54.3) <0.001 * 
   African American, n (%) 661 (23.2) 168 (23.6) 168 (23.6) 162 (22.8) 163 (22.9) 0.979 
   High school or lower education, n (%)  1524 (53.6) 377 (52.9) 388 (54.4) 370 (52.2) 389 (54.7) 0.745 
   Study center      0.002 * 
       Forsyth County, North Carolina 590 (20.7) 136 (19.1) 120 (16.8) 165 (23.3) 169 (23.8)  
       Jackson, Mississippi 617 (21.7) 155 (21.8) 161 (22.6) 150 (21.2) 151 (21.2)  
       Suburban Minneapolis, Minnesota 862 (27.3) 195 (27.4) 232 (32.5) 208 (29.3) 227 (31.9)  
       Washington County, Maryland 776 (27.0) 226 (31.7) 200 (28.1) 186 (26.2) 164 (23.1)  
   Body Mass Index (kg/m2) 28.0 ± 4.5 29.0 ± 4.6 28.3 ± 4.5 27.7 ± 4.4 26.8 ± 4.1 <0.001 * 
   Systolic blood pressure (mmHg) 130.4 ± 17.0 122.6 ± 15.3 128.1 ± 15.3 131.8 ± 15.4 139.1 ± 17.5 <0.001 * 
   Diastolic blood pressure (mmHg) 66.7 ± 9.9 63.3 ± 9.4 66.0 ± 9.3 67.2 ± 9.5 70.2 ± 10.3 <0.001 * 
   Antihypertensive medication, n (%)  1969 (69.2) 490 (68.8) 496 (69.6) 500 (70.5) 483 (67.9) 0.751 
   Diabetes, n (%) 956 (33.6) 228 (32.0) 244 (34.2) 231 (32.6) 253 (35.6) 0.475 
   Current smoker, n (%) 153 (5.4) 51 (7.2) 36 (5.0) 45 (6.3) 21 (3.0) 0.003* 
   Current drinker, n (%) 1432 (50.3) 361 (50.7) 361 (50.6) 353 (49.8) 357 (50.2) 0.985 
   Physical activity score  2.3 ± 0.6 2.3 ± 0.7 2.3 ± 0.6 2.3 ± 0.7 2.3 ± 0.6 0.367 
   Total cholesterol (mmol/L) 4.8 ± 1.1 4.8 ± 1.0 4.9 ± 1.0 4.8 ± 1.1 4.8 ± 1.1 0.914 
   Reduced kidney function, n (%) 686 (24.1) 177 (24.9) 150 (21.0) 172 (24.3) 187 (26.3) 0.123 
   Kidney damage, n (%) 425 (14.9) 74 (10.4) 88 (12.3) 115 (16.2) 148 (20.8) <0.001 * 
   LV hypertrophy, n (%) 234 (8.2) 68 (9.6) 58 (8.1) 46 (6.5) 62 (8.7) 0.193 
   Concentric remodeling, n (%) 1274 (44.8) 300 (42.1) 306 (42.9) 330 (46.5) 338 (47.5) 0.107 
   Diastolic dysfunction, n (%) 288 (10.1) 82 (11.5) 65 (9.1) 68 (9.6) 73 (10.3) 0.466 
Values are expressed as mean ± SD/median (IQR) for continuous variables, n (%) for categorical variables. * P <0.05 (two sided) 





Supplementary Table 4. Demographic and clinical characteristics of study participants overall and according to baPWV 















   Age (years) 75.0 ± 4.9 73.3 ± 4.3 74.5 ± 4.8 75.4 ± 4.7 76.8 ± 5.2 <0.001 * 
   Females, n (%) 1772 (62.3) 444 (62.4) 442 (62.2) 434 (60.9) 452 (63.8) 0.738 
   African American, n (%) 661 (23.2) 164 (23.0) 177 (24.9) 183 (25.7) 137 (19.3) 0.023 * 
   High school or lower education, n (%)  1524 (53.6) 347 (48.7) 370 (52.0) 389 (54.6) 418 (59.0) 0.001 * 
   Study center      <0.001 * 
       Forsyth County, North Carolina 590 (20.7) 115 (16.2) 131 (18.4) 146 (20.5) 198 (27.9)  
       Jackson, Mississippi 617 (21.7) 154 (21.6) 168 (23.6) 171 (24.0) 124 (17.5)  
       Suburban Minneapolis, Minnesota 862 (27.3) 219 (30.8) 216 (30.4) 205 (28.8) 222 (31.3)  
       Washington County, Maryland 776 (27.0) 224 (31.5) 196 (27.6) 191 (26.8) 165 (23.3)  
   Body Mass Index (kg/m2) 28.0 ± 4.5 28.7 ± 4.8 28.3 ± 4.4 27.9 ± 4.4 26.9 ± 4.1 <0.001 * 
   Systolic blood pressure (mmHg) 130.4 ± 17.0 121.8 ± 14.9 127.9 ± 14.7 133.0 ± 16.1 138.9 ± 17.3 <0.001 * 
   Diastolic blood pressure (mmHg) 66.7 ± 9.9 64.2 ± 9.2 65.7 ± 9.5 67.6 ± 10.1 69.2 ± 10.2 <0.001 * 
   Antihypertensive medication, n (%)  1969 (69.2) 475 (66.7) 493 (69.3) 512 (71.8) 489 (69.0) 0.224 
   Diabetes, n (%) 956 (33.6) 223 (31.3) 248 (34.9) 246 (34.5) 239 (33.7) 0.485 
   Current smoker, n (%) 153 (5.4) 58 (8.1) 30 (4.2) 38 (5.3) 27 (3.8) 0.001 * 
   Current drinker, n (%) 1432 (50.3) 374 (52.5) 360 (50.6) 357 (50.1) 341 (48.1) 0.417 
   Physical activity score  2.3 ± 0.6 2.3 ± 0.7 2.3 ± 0.7 2.3 ± 0.6 2.2 ± 0.6 0.121 
   Total cholesterol (mmol/L) 4.8 ± 1.1 4.8 ± 1.0 4.8 ± 1.0 4.8 ± 1.0 4.9 ± 1.1 0.403 
   Reduced kidney function, n (%) 686 (24.1) 172 (24.2) 163 (22.9) 172 (24.1) 179 (25.2) 0.790 
   Kidney damage, n (%) 425 (14.9) 70 (9.8) 95 (13.4) 122 (17.1) 138 (19.5) <0.001 * 
   LV hypertrophy, n (%) 234 (8.2) 62 (8.7) 52 (7.3) 57 (8.0) 63 (8.9) 0.691 
   Concentric remodeling, n (%) 1274 (44.8) 289 (40.6) 318 (44.7) 323 (45.3) 344 (48.5) 0.027 * 
   Diastolic dysfunction, n (%) 288 (10.1) 83 (11.7) 69 (9.7) 73 (10.2) 63 (8.9) 0.364 
Values are expressed as mean ± SD/median (IQR) for continuous variables, n (%) for categorical variables. * P <0.05 (two sided) 
Abbreviations: SD, standard deviation; IQR, interquartile range; baPWV, brachial-ankle pulse wave velocity. 
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Supplementary Table 5. Demographic and clinical characteristics of study participants overall and according to faPWV 















   Age (years) 75.0 ± 4.9 74.9 ± 4.9 74.5 ± 4.7 75.0 ± 5.0 75.6 ± 5.1 0.001 * 
   Females, n (%) 1772 (62.3) 447 (62.7) 439 (61.7) 439 (61.6) 447 (63.1) 0.916 
   African American, n (%) 661 (23.2) 233 (32.7) 172 (24.2) 145 (20.3) 111 (15.7) <0.001 * 
   High school or lower education, n (%)  1524 (53.6) 394 (55.3) 362 (50.9) 364 (51.1) 404 (57.1) 0.044* 
   Study center      <0.001 * 
       Forsyth County, North Carolina 590 (20.7) 103 (14.5) 123 (17.3) 155 (21.7) 209 (29.5)  
       Jackson, Mississippi 617 (21.7) 220 (30.9) 161 (22.6) 136 (19.1) 100 (14.1)  
       Suburban Minneapolis, Minnesota 862 (27.3) 191 (26.8) 239 (33.6) 234 (32.8) 198 (28.0)  
       Washington County, Maryland 776 (27.0) 199 (27.9) 188 (26.4) 188 (26.4) 201 (28.4)  
   Body Mass Index (kg/m2) 28.0 ± 4.5 29.3 ± 4.7 28.1 ± 4.5 27.5 ± 4.2 27.0 ± 4.1 <0.001 * 
   Systolic blood pressure (mmHg) 130.4 ± 17.0 126.5 ± 16.5 128.9 ± 16.4 131.4 ± 16.3 134.8 ± 17.6 <0.001 * 
   Diastolic blood pressure (mmHg) 66.7 ± 9.9 63.3 ± 9.3 65.4 ± 9.3 67.8 ± 9.6 70.1 ± 10.2 <0.001 * 
   Antihypertensive medication, n (%)  1969 (69.2) 547 (76.7) 486 (68.4) 483 (67.7) 453 (64.0) <0.001 * 
   Diabetes, n (%) 956 (33.6) 271 (38.0) 247 (34.7) 229 (32.1) 209 (29.5) 0.006* 
   Current smoker, n (%) 153 (5.4) 57 (8.0) 36 (5.1) 29 (4.1) 31 (4.4) 0.004* 
   Current drinker, n (%) 1432 (50.3) 309 (43.3) 369 (51.9) 382 (53.6) 372 (52.5) <0.001 * 
   Physical activity score 2.3 ± 0.6 2.2 ± 0.6 2.3 ± 0.7 2.3 ± 0.6 2.3 ± 0.6 <0.001 
   Total cholesterol (mmol/L) 4.8 ± 1.1 4.8 ± 1.0 4.8 ± 1.0 4.8 ± 1.1 4.9 ± 1.1 0.025 * 
   Reduced kidney function, n (%) 686 (24.1) 206 (28.9) 174 (24.5) 161 (22.6) 145 (20.5) 0.002* 
   Kidney damage, n (%) 425 (14.9) 106 (14.9) 102 (14.3) 113 (15.8) 104 (14.7) 0.874 
   LV hypertrophy, n (%) 234 (8.2) 79 (11.1) 58 (8.2) 46 (6.5) 51 (7.2) 0.009* 
   Concentric remodeling, n (%) 1274 (44.8) 327 (45.9) 291 (40.9) 325 (45.6) 331 (46.8) 0.116 
   Diastolic dysfunction, n (%) 288 (10.1) 96 (13.5) 69 (9.7) 67 (9.4) 56 (7.9) 0.004* 
Values are expressed as mean ± SD/median (IQR) for continuous variables, n (%) for categorical variables. * P <0.05 (two sided) 




Supplementary Table 6. Correlation coefficients between PWV measures 
 cfPWV hcPWV hfPWV haPWV baPWV faPWV 
cfPWV 1.000 0.016 0.853 0.655 0.506 -0.008 
hcPWV 0.016 1.000 0.427 0.339 0.088 0.041 
hfPWV 0.853 0.427 1.000 0.766 0.487 -0.001 
haPWV 0.655 0.339 0.766 1.000 0.763 0.526 
baPWV 0.506 0.088 0.487 0.763 1.000 0.610 
faPWV -0.008 0.041 -0.001 0.526 0.610 1.000 
Abbreviations: PWV, pulse wave velocity; cfPWV, carotid-femoral PWV; hcPWV, heart-carotid PWV; hfPWV, heart-femoral PWV; haPWV, heart-











PWV quartile categories b 
Q1 Q2 Q3 Q4 
𝛽𝛽c (95%CI) Ref 𝛽𝛽(95%CI) 𝛽𝛽(95%CI) 
Unadjuste
d model a 
cfPWV 0.031 (-0.069, 0.130) 0 0.047 (-0.053, 0.146)  0.222 (0.123, 0.322) * 
hcPWV 0.086 (-0.013, 0.186) 0 0.032 (-0.068, 0.132) 0.085 (-0.015, 0.185) 
hfPWV  0.121 (0.022, 0.220) * 0  0.117 (0.017, 0.216) *  0.234 (0.134, 0.333) * 
haPWV 0.072 (-0.028, 0.171) 0 0.046 (-0.053, 0.146)  0.185 (0.086, 0.285) * 
baPWV 0.027 (-0.073, 0.126) 0 0.044 (-0.056, 0.143)  0.200 (0.100, 0.299) * 
faPWV 0.070 (-0.030, 0.169) 0 0.045 (-0.055, 0.145) 0.011 (-0.089, 0.111) 
Abbreviations: PWV, pulse wave velocity; cfPWV, carotid-femoral PWV; hcPWV, heart-carotid PWV; hfPWV, heart-femoral PWV; haPWV, heart-
ankle PWV; baPWV, brachial-ankle PWV; faPWV, femoral-ankle PWV; NT-pro BNP, N-terminal pro-B-type natriuretic peptide. 
a. Univariate linear regression with no adjustment. 
b. Quartiles for PWV measures:  
    cfPWV: Q1, ≤950.5 (n=716); Q2, 950.5-≤1122 (n=707); Q3, 1122-≤1320.5 (n=711); Q4, >1320.5 (n=711) 
    hcPWV: Q1, ≤904  (n=712); Q2, 904-≤1059.5  (n=712); Q3, 1059.5-≤1274.5  (n=710); Q4, >1274.5  (n=711) 
    hfPWV: Q1, ≤996 (n=712); Q2, 996-≤1132.5 (n=711); Q3, 1132.5-≤1282.5 (n=711); Q4, >1282.5 (n=711) 
    haPWV: Q1, ≤1021 (n=712); Q2, 1021-≤1113 (n=713); Q3, 1113-≤1208.5  (n=709); Q4, >1208.5  (n=711) 
    baPWV: Q1, ≤1538 (n=712); Q2, 1538-≤1728 (n=711); Q3, 1728-≤1948 (n=713); Q4, >1948 (n=709) 
    faPWV: Q1, ≤999 (n=713); Q2, 999-≤1108  (n=711); Q3, 1108-≤1224  (n=713); Q4, >1224  (n=708) 
c. Linear regression coefficient: It indicates the difference in log NT-proBNP between each PWV quartile category and the reference category (Q2). 


















PWV quartile categories b 
Q1 Q2 Q3 Q4 
𝛽𝛽c (95%CI) Ref 𝛽𝛽(95%CI) 𝛽𝛽(95%CI) 
Unadjusted 
model a 
cfPWV -0.053 (-0.115, 0.009) 0  0.095 (0.033, 0.157) *   0.183 (0.121, 0.246) * 
hcPWV   -0.064 (-0.126, -0.001) * 0  0.095 (0.033, 0.158) *   0.128 (0.066, 0.190) * 
hfPWV -0.055 (-0.117, 0.007) 0  0.079 (0.017, 0.141) *   0.231 (0.169, 0.293) * 
haPWV -0.003 (-0.065, 0.060) 0 0.061 (-0.002, 0.123)   0.130 (0.068, 0.193) * 
baPWV -0.020 (-0.082, 0.043) 0  0.102 (0.039, 0.165) *   0.069 (0.006, 0.131) * 
faPWV   0.093 (0.030, 0.155) * 0 -0.004 (-0.066, 0.059) -0.025 (-0.088, 0.038) 
Abbreviations: PWV, pulse wave velocity; cfPWV, carotid-femoral PWV; hcPWV, heart-carotid PWV; hfPWV, heart-femoral PWV; haPWV, heart-
ankle PWV; baPWV, brachial-ankle PWV; faPWV, femoral-ankle PWV; hs-cTnT, high-sensitivity troponin T. 
Red & bold indicates statistically significant results. 
a. Univariate linear regression with no adjustment. 
b. Quartiles for PWV measures:  
    cfPWV: Q1, ≤950.5 (n=716); Q2, 950.5-≤1122 (n=707); Q3, 1122-≤1320.5 (n=711); Q4, >1320.5 (n=711) 
    hcPWV: Q1, ≤904  (n=712); Q2, 904-≤1059.5  (n=712); Q3, 1059.5-≤1274.5  (n=710); Q4, >1274.5  (n=711) 
    hfPWV: Q1, ≤996 (n=712); Q2, 996-≤1132.5 (n=711); Q3, 1132.5-≤1282.5 (n=711); Q4, >1282.5 (n=711) 
    haPWV: Q1, ≤1021 (n=712); Q2, 1021-≤1113 (n=713); Q3, 1113-≤1208.5  (n=709); Q4, >1208.5  (n=711) 
    baPWV: Q1, ≤1538 (n=712); Q2, 1538-≤1728 (n=711); Q3, 1728-≤1948 (n=713); Q4, >1948 (n=709) 
    faPWV: Q1, ≤999 (n=713); Q2, 999-≤1108  (n=711); Q3, 1108-≤1224  (n=713); Q4, >1224  (n=708) 
c. Linear regression coefficient: It indicates the difference in log hs-cTnT between each PWV quartile category and the reference category (Q2). 













Supplementary Table 9. Unadjusted odds ratios (95% confidence intervals) of elevated NT-proBNP (≥300pg/ml) 
according to measures of regional pulse wave velocity (in quartiles) 
 Regional 
PWV 
PWV quartile categories b 
Q1 Q2 Q3 Q4 
ORc (95%CI) Ref OR (95%CI) OR (95%CI) 
Unadjusted 
model a 
cfPWV 1.056 (0.763, 1.461) 1 1.093 (0.791, 1.510)   1.639 (1.211, 2.220) * 
hcPWV   1.634 (1.192, 2.239) * 1 1.255 (0.903, 1.743)   1.449 (1.052, 1.998) * 
hfPWV 1.053 (0.764, 1.451) 1 1.069 (0.776, 1.471)   1.490 (1.101, 2.017) * 
haPWV 1.251 (0.910, 1.718) 1 1.064 (0.767, 1.476)   1.581 (1.163, 2.148) * 
baPWV 1.141 (0.828, 1.573) 1 1.125 (0.816, 1.552)   1.543 (1.136, 2.095) * 
faPWV 1.155 (0.849, 1.571) 1 1.141 (0.839, 1.553) 1.005 (0.733, 1.378) 
Abbreviations: PWV, pulse wave velocity; cfPWV, carotid-femoral PWV; hcPWV, heart-carotid PWV; hfPWV, heart-femoral PWV; haPWV, heart-
ankle PWV; baPWV, brachial-ankle PWV; faPWV, femoral-ankle PWV; NT-pro BNP, N-terminal pro-B-type natriuretic peptide. 
Red & bold indicates statistically significant results. 
a. Univariate logistic regression with no adjustment. 
b. Quartiles for PWV measures:  
    cfPWV: Q1, ≤950.5 (n=716); Q2, 950.5-≤1122 (n=707); Q3, 1122-≤1320.5 (n=711); Q4, >1320.5 (n=711) 
    hcPWV: Q1, ≤904  (n=712); Q2, 904-≤1059.5  (n=712); Q3, 1059.5-≤1274.5  (n=710); Q4, >1274.5  (n=711) 
    hfPWV: Q1, ≤996 (n=712); Q2, 996-≤1132.5 (n=711); Q3, 1132.5-≤1282.5 (n=711); Q4, >1282.5 (n=711) 
    haPWV: Q1, ≤1021 (n=712); Q2, 1021-≤1113 (n=713); Q3, 1113-≤1208.5  (n=709); Q4, >1208.5  (n=711) 
    baPWV: Q1, ≤1538 (n=712); Q2, 1538-≤1728 (n=711); Q3, 1728-≤1948 (n=713); Q4, >1948 (n=709) 
    faPWV: Q1, ≤999 (n=713); Q2, 999-≤1108  (n=711); Q3, 1108-≤1224  (n=713); Q4, >1224  (n=708) 
c. Odds ratio in logistic regression: It indicates the ratio of odds for elevated NT-proBNP level between each PWV quartile category and the 










Supplementary Table 10. Unadjusted odds ratios (95% confidence intervals) of elevated hs-cTnT (≥14 ng/L) according to 
measures of regional pulse wave (in quartiles) 
 Regional 
PWV 
PWV quartile categories b 
Q1 Q2 Q3 Q4 
ORc (95%CI) Ref OR (95%CI) OR (95%CI) 
Unadjusted 
model a 
cfPWV 0.922 (0.718, 1.184) 1   1.335 (1.051, 1.696) *   1.824 (1.445, 2.304) * 
hcPWV 0.791 (0.616, 1.015) 1   1.397 (1.107, 1.765) *   1.460 (1.157, 1.841) * 
hfPWV 0.934 (0.726, 1.202) 1   1.312 (1.031, 1.670) *   2.038 (1.614, 2.573) * 
haPWV 1.058 (0.829, 1.350) 1 1.224 (0.963, 1.556)   1.648 (1.305, 2.081) * 
baPWV 0.897 (0.704, 1.142) 1 1.214 (0.962, 1.533) 1.241 (0.983, 1.567) 
faPWV  1.385 (1.097, 1.748) * 1 1.105 (0.871, 1.402) 1.060 (0.834, 1.347) 
Abbreviations: PWV, pulse wave velocity; cfPWV, carotid-femoral PWV; hcPWV, heart-carotid PWV; hfPWV, heart-femoral PWV; haPWV, heart-
ankle PWV; baPWV, brachial-ankle PWV; faPWV, femoral-ankle PWV; hs-cTnT, high-sensitivity troponin T. 
Red & bold indicates statistically significant results. 
a. Univariate logistic regression with no adjustment. 
b. Quartiles for PWV measures:  
    cfPWV: Q1, ≤950.5 (n=716); Q2, 950.5-≤1122 (n=707); Q3, 1122-≤1320.5 (n=711); Q4, >1320.5 (n=711) 
    hcPWV: Q1, ≤904  (n=712); Q2, 904-≤1059.5  (n=712); Q3, 1059.5-≤1274.5  (n=710); Q4, >1274.5  (n=711) 
    hfPWV: Q1, ≤996 (n=712); Q2, 996-≤1132.5 (n=711); Q3, 1132.5-≤1282.5 (n=711); Q4, >1282.5 (n=711) 
    haPWV: Q1, ≤1021 (n=712); Q2, 1021-≤1113 (n=713); Q3, 1113-≤1208.5  (n=709); Q4, >1208.5  (n=711) 
    baPWV: Q1, ≤1538 (n=712); Q2, 1538-≤1728 (n=711); Q3, 1728-≤1948 (n=713); Q4, >1948 (n=709) 
    faPWV: Q1, ≤999 (n=713); Q2, 999-≤1108  (n=711); Q3, 1108-≤1224  (n=713); Q4, >1224  (n=708) 
c. Odds ratio in logistic regression: It indicates the ratio of odds for elevated hs-cTnT level between each PWV quartile category and the reference 























































Patients at visit 5  
(n=6,538) 
Patients included in analysis  
(n=2,845) 
Patients were excluded (n=3,693): 
1. Race is not Caucasian or African American (n=18) 
2. PWV variables (cfpwv, hfpwv, hcpwv, rhapwv, lhapwv, 
lbapwv, rbapwv, rfapwv, or lfapwv) missing (n=1,704) 
3. Participants with clinical conditions questioning the 
validity of PWV measurement (n=387): 
a. BMI>40 or BMI missing (n=143) 
b. Severe arrhythmia (n=133) 
c. Self-reported aortic revascularization surgery 
(aorta repaired) (n=48) 
d. Peripheral revascularization prior to or at visit 5 
date (n=24) 
e. Aortic aneurysm  (n=2) 
f. Aortic Stenosis and aortic regurgitation (n=34) 
g. Ejection fraction<30% (n=3) 
4. PWV values (cfpwv, hcpwv, hfpwv, hapwv, bapwv, or 
fapwv) greater than 3 standard deviations away from 
the mean (n=305) 
5. Those with prevalent cardiac disease before or during 
visit 5 (prevalent heart failure, coronary heart disease) 
(n=611) 
6. NT-proBNP missing (n=94) 
7. hs-cTnT missing (n=1) 




Supplement Figure 2. Predicted log NT-proBNP and hs-cTnT with regional PWV with 
splines by quartiles without adjustment  
a.  b.  
c.  d.  
e.   f.  
g.   h.  
i.     j.  
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